Are Glaxosmi. Pharma latest results good or bad?
GlaxoSmithKline Pharmaceuticals' latest results are concerning, with net sales, profit before tax, and profit after tax all declining compared to previous quarters, indicating a challenging financial environment. The overall outlook appears negative based on these trends.
GlaxoSmithKline Pharmaceuticals has reported its financial results for the quarter ending June 2025, highlighting several operational trends. The company's net sales for the quarter were recorded at Rs 805.17 crore, which reflects a decline compared to the average net sales of the previous four quarters. This figure represents the lowest quarterly sales in the past five quarters, indicating a challenging sales environment.Profit Before Tax (PBT) for the quarter was Rs 235.26 crore, showing a decrease from the average PBT of the last four quarters. Similarly, Profit After Tax (PAT) was reported at Rs 205.01 crore, also lower than the average PAT of the previous periods. These results suggest a consistent downward trend in profitability metrics.
Additionally, the Debtors Turnover Ratio has reached its lowest level at 12.82 times, indicating a decline over the last five half-yearly periods. While there was an increase in non-operating income to Rs 43.72 crore, this rise may not be indicative of a sustainable trend in the long term.
Overall, the financial outlook for GlaxoSmithKline Pharmaceuticals appears to be challenging based on these results. The company saw an adjustment in its evaluation in light of the reported financial data.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
